Sarepta, Australian university collaborate on DMD drug development

04/15/2013 | Pharmaceutical Business Review Online

Sarepta Therapeutics obtained exclusive, global rights to the University of Western Australia's patent portfolio of investigational drug therapies for Duchenne muscular dystrophy. The firm will use the patents to develop exon-skipping treatments for DMD. The university will get as much as $7.1 million in upfront and milestone fees plus sales royalties.

View Full Article in:

Pharmaceutical Business Review Online

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Senior Legal Counsel
Fort Worth, TX
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Senior Manager, Clinical Affairs - Advanced Technology
Edwards Lifesciences
Irvine, CA